Zonagen cleared to begin European Proellex trial
The European phase II study will enroll 40 women and compare three doses of double blinded Proellex against open label Lupron, the current standard of care, for up
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.